Conference Coverage

Clearer picture emerging of renal impact of SGLT2s


 

EXPERT ANALYSIS FROM WCIRDC 2017


Upcoming trials of renal endpoints to look out for, he said, include the CREDENCE study (results expected in 2019), DAPA-CKD, which is in the recruitment stage, and a new outcome study to evaluate the effect of empagliflozin for the treatment of people with chronic kidney disease. “This is an expanding area in the renal and cardiovascular world that we will hear a lot more about in the next 3-5 years,” he said.

Dr. Cherney reported consulting fees and/or honoraria from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Merck, Mitsubishi Tanabe, and Sanofi.

Pages

Recommended Reading

VIDEO: Pioglitazone benefited NASH patients with and without T2DM
MDedge Family Medicine
Dexcom G6 gets FDA nod
MDedge Family Medicine
FDA approves highest capacity insulin pen
MDedge Family Medicine
Robocalls increase diabetic retinopathy screenings in low-income patients
MDedge Family Medicine
MDedge Daily News: Why low-calorie sucralose may fuel weight gain
MDedge Family Medicine
MDedge Daily News: How European data privacy rules may cost you
MDedge Family Medicine
Metformin reduces preterm births, late miscarriages in PCOS
MDedge Family Medicine
Hope and hype: Inside the push for wearable diabetes technology
MDedge Family Medicine
Sensitivity of vibration-based neuropathy detectors varies widely
MDedge Family Medicine
Being overweight as a child increases the risk of developing diabetes
MDedge Family Medicine